News Feed
StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley a Good Trip for Psychedelic Drugs, Analysts and Investors Agree
Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion—of which Lilly will pay $2.8 billion upfront. The deal, set to close in the third quarter, expands Lilly’s neuroscience portfolio by adding AtaiBeckley's…
Opinion: Beware the unintended consequences of testosterone screening for military servicemembers
“I fear that the widespread rollout of testosterone screening may lead to some surprising and unintended consequences,” writes a urologist who studies testosterone.
Organ Aging Linked to Breakdown in Immune Cell Interaction and Senescent Neutrophil Clearance
A study in mice and in human cells found that blocking a single receptor on tissue-resident macrophages promoted clearance of accumulating senescent neutrophils, preserved the youthfulness of multiple organs in mice, and substantially slowed…
News
2647 results
STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug
You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening at the American Association of Cancer Researchers' annual meeting. Sign up here.We’re…
STAT+: The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades
Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna Stokes, survival time doubled.
How Trump is pushing psychedelics reform through the health agencies
Trump directed the federal government to rush access to psychedelic treatments and reevaluate their status as controlled substances.
Opinion: The podcast bringing together MAHA and public health for hard conversations
“These sides aren't talking to each other. And there's a lot riding on it”: The hosts of “Why Should I Trust You?” on bringing together MAHA and public health.
Optimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role
As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but hopeful.”
Investigating Functional Changes in the Frontotemporal Cortex of Patients With Major Depressive Disorder Following Electroconvulsive Therapy or Magnetic Seizure Therapy Using Functional Near-infrared Spectroscopy (fNIRS)
Conditions: Major Depressive Disorder (MDD) Interventions: Other: Electroconvulsive Therapy; Other: Magnetic Seizure Therapy Sponsors: The Second Hospital of Anhui Medical University Not yet recruiting
Recording Stress Biomarkers in Autism Spectrum Disorders
Conditions: Autism Spectrum Disorder With Intellectual Deficiency Sponsors: Universite Cote d'Azur Recruiting
Site-specific engineering to produce CAR T cells in vivo
Nature Biotechnology, Published online: 17 April 2026; doi:10.1038/s41587-026-03117-0Site-specific engineering to produce CAR T cells in vivo
FDA approves wearable device for pancreatic cancer
Nature Biotechnology, Published online: 17 April 2026; doi:10.1038/s41587-026-03102-7FDA approves wearable device for pancreatic cancer
World’s first two iPSC therapies in Japan
Nature Biotechnology, Published online: 17 April 2026; doi:10.1038/s41587-026-03105-4World’s first two iPSC therapies in Japan
Biotech news from around the world
Nature Biotechnology, Published online: 17 April 2026; doi:10.1038/s41587-026-03103-6Biotech news from around the world
Plastic-eating fungi dig diapers
Nature Biotechnology, Published online: 17 April 2026; doi:10.1038/s41587-026-03096-2Plastic-eating fungi dig diapers
Publisher Correction: Reliability of LLMs as medical assistants for the general public: a randomized preregistered study
Nature Medicine, Published online: 17 April 2026; doi:10.1038/s41591-026-04404-8Publisher Correction: Reliability of LLMs as medical assistants for the general public: a randomized preregistered study
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Nature Medicine, Published online: 17 April 2026; doi:10.1038/s41591-026-04405-7Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Expression of Concern for: Nicotine breaks down preformed Alzheimer’s β-amyloid fibrils in vitro
Expression of Concern for: “Nicotine breaks down preformed Alzheimer’s β-amyloid fibrils in vitro,” by Ono et al. (Biol Psychiatry 2002; 52:880–886); https://doi.org/10.1016/S0006-3223(02)01417-8.
Impact of Prescribed and Self-Selected Music Interventions on Stress, Sleep, Heart Rate Variability, and Brain Connectivity in Surgeons Using 7-Tesla Functional Magnetic Resonance Imaging and Wearable Actigraphy: Multimodal Feasibility Randomized Controlled Trial
Background: Stress, sleep deprivation, and burnout are significant safety risks for acute care surgeons, negatively impacting performance, well-being, and clinical outcomes. Objective: This pilot randomized controlled trial aimed to measure neurophysiological effects of prescribed music (PM) and self-selected music (SSM)…
Exploring Influencing Factors of Medication Adherence Among Chinese Patients With Alzheimer Disease: Delphi Study Informing Future Artificial Intelligence–Supported Interventions
Background: Alzheimer disease (AD) affects cognition, treatment adherence, family connections, and health care resource allocation. Most patients with AD have low adherence to medication therapy due to the limitations associated with cognitive impairment. Therefore, increasing the involvement of patients and…
Development of iGET Living, a Digital Graded Exposure Intervention for Youth With Chronic Pain: Multiphase User-Centered Design and Pilot Study
Background: Pediatric chronic pain affects up to one-third of youth and is associated with significant disruptions in social, emotional, and behavioral functioning. Although behavioral treatments are effective, access remains limited due to geographic, financial, and systemic barriers. Digital behavioral health…
STAT+: A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment
"I do think it's a revolution," said Paul Oberstein of NYU Langone's Perlmutter Cancer Center.